81 related articles for article (PubMed ID: 21183545)
1. Proton inactivation of melanoma cells enhanced by fotemustine.
Ristić-Fira A; Korićanac L; Žakula J; Keta O; Iannolo G; Cuttone G; Petrović I
Radiat Prot Dosimetry; 2011 Feb; 143(2-4):503-7. PubMed ID: 21183545
[TBL] [Abstract][Full Text] [Related]
2. Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
Petrović IM; Korićanac LB; Todorović DV; Ristić-Fira AM; Valastro LM; Privitera G; Cuttone G
Ann N Y Acad Sci; 2007 Jan; 1095():154-64. PubMed ID: 17404028
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour activity of fotemustine and protons in combination with bevacizumab.
Korićanac LB; Zakula JJ; Petrović IM; Valastro LM; Cirrone GA; Cuttone G; Ristić-Fira AM
Chemotherapy; 2010; 56(3):214-22. PubMed ID: 20551638
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the inhibitory effects of different radiation qualities or chemotherapeutic agents on a human melanoma cell line.
Ristić-Fira AM; Petrović IM; Korićanac LB; Valastro LM; Privitera G; Cuttone G
Phys Med; 2008 Dec; 24(4):187-95. PubMed ID: 18514560
[TBL] [Abstract][Full Text] [Related]
5. Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.
Ristić-Fira AM; Korićanac LB; Zakula JJ; Valastro LM; Iannolo G; Privitera G; Cuttone G; Petrović IM
J Exp Clin Cancer Res; 2009 Apr; 28(1):50. PubMed ID: 19358719
[TBL] [Abstract][Full Text] [Related]
6. Response of a radioresistant human melanoma cell line along the proton spread-out Bragg peak.
Petrović I; Ristić-Fira A; Todorović D; Korićanac L; Valastro L; Cirrone P; Cuttone G
Int J Radiat Biol; 2010 Sep; 86(9):742-51. PubMed ID: 20597839
[TBL] [Abstract][Full Text] [Related]
7. Response of a human melanoma cell line to low and high ionizing radiation.
Ristic-Fira AM; Todorovic DV; Koricanac LB; Petrovic IM; Valastro LM; Cirrone PG; Raffaele L; Cuttone G
Ann N Y Acad Sci; 2007 Jan; 1095():165-74. PubMed ID: 17404029
[TBL] [Abstract][Full Text] [Related]
8. Radiobiological analysis of human melanoma cells on the 62 MeV CATANA proton beam.
Petrović I; Ristić-Fira A; Todorović D; Valastro L; Cirrone P; Cuttone G
Int J Radiat Biol; 2006 Apr; 82(4):251-65. PubMed ID: 16690593
[TBL] [Abstract][Full Text] [Related]
9. Early effects of gamma rays and protons on human melanoma cell viability and morphology.
Todorović D; Petrović I; Todorović M; Cuttone G; Ristić-Fira A
J Microsc; 2008 Dec; 232(3):517-21. PubMed ID: 19094032
[TBL] [Abstract][Full Text] [Related]
10. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of HTB63 human melanoma cells by irradiation with protons and gamma rays.
Ristic-Fira A; Petrovic I; Todorovic D; Koricanac L; Vujèic M; Demajo M; Sabini G; Cirrone P; Cuttone G
Oncol Rep; 2004 Dec; 12(6):1323-8. PubMed ID: 15547758
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
Voelter V; Schalenbourg A; Pampallona S; Peters S; Halkic N; Denys A; Goitein G; Zografos L; Leyvraz S
Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
Siegel R; Hauschild A; Kettelhack C; Kähler KC; Bembenek A; Schlag PM
Eur J Surg Oncol; 2007 Jun; 33(5):627-32. PubMed ID: 17196362
[TBL] [Abstract][Full Text] [Related]
14. [Contribution of a new nitrosourea compound: fotemustine].
Boaziz C
Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
[TBL] [Abstract][Full Text] [Related]
15. [Malignant melanoma of the uvea].
Boaziz C; Mazeron JJ; Morere JF; Breau JL; Israël L
Bull Cancer; 1993 Jul; 80(7):577-83. PubMed ID: 8204938
[TBL] [Abstract][Full Text] [Related]
16. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
18. Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study.
Bröcker EB; Bohndorf W; Kämpgen E; Trcka J; Messer P; Tilgen W; Engenhart K; Flentje M
Melanoma Res; 1996 Oct; 6(5):399-401. PubMed ID: 8908601
[TBL] [Abstract][Full Text] [Related]
19. [Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].
Fischel JL; Barbé V; Berlion M; Formento P; Berrile J; Bizzari JP; Milano G
Bull Cancer; 1994 Jul; 81(7):599-604. PubMed ID: 7742602
[TBL] [Abstract][Full Text] [Related]
20. [New toxicity of fotemustine: diffuse interstitial lung disease].
Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
